[{"orgOrder":0,"company":"Care Access Research","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Abemaciclib","moa":"||CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Care Access Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Care Access Research \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Care Access Research \/ Eli Lilly"},{"orgOrder":0,"company":"Care Access Research","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"AZD7442","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Care Access Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Care Access Research \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Care Access Research \/ AstraZeneca"}]

Find Clinical Drug Pipeline Developments & Deals by Care Access Research

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          APGA Annual Conference
                          Not Confirmed
                          APGA Annual Conference
                          Not Confirmed

                          Details : Lilly has tapped Care Access in its phase III breast cancer clinical trial, eMonarcHER, designed to evaluate the safety and efficacy of Abemaciclib (LY2835219) in participants with hormone receptor positive and human epidermal receptor 2 positive, early ...

                          Product Name : LY2835219

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 28, 2021

                          Lead Product(s) : Abemaciclib,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Eli Lilly

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          APGA Annual Conference
                          Not Confirmed
                          APGA Annual Conference
                          Not Confirmed

                          Details : Care Access is supporting the Phase III clinical trial called STORM CHASER, which will assess the safety and efficacy of AZD7442 for post-exposure prophylaxis and pre-emptive treatment in approximately 1,125 participants in the US and UK.

                          Product Name : AZD7442

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          January 26, 2021

                          Lead Product(s) : AZD7442

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank